Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Efficacy, Team × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 242 Neoplasms 162 Colorectal Neoplasms 118 Stomach Neoplasms 100 Uterine Cervical Neoplasms 90 Carcinoma, Non-Small-Cell Lung 82 Prostatic Neoplasms 77 Lung Neoplasms 71 Carcinoma, Hepatocellular 66 Rectal Neoplasms 55 Ovarian Neoplasms 49 Esophageal Neoplasms 47 Pancreatic Neoplasms 45 Colonic Neoplasms 43 Recurrence 35 Neoplasm Metastasis 35 Head and Neck Neoplasms 34 Multiple Myeloma 33 Motor Activity 32 Endometrial Neoplasms 32 Precursor Cell Lymphoblastic Leukemia-Lymphoma 31 Polycystic Ovary Syndrome 31 Lymphoma 30 Melanoma 29 Urinary Bladder Neoplasms 28 Thyroid Neoplasms 28 Leukemia, Myeloid, Acute 26 Small Cell Lung Carcinoma 25 Lymphoma, Non-Hodgkin 24 Nasopharyngeal Carcinoma 23

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡